Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
By Peter Attia, G. Phan, A. Maker, M. Robinson, M. Quezado, Jie Yang, R. Sherry, S. Topalian, U. Kammula, R. Royal and 7 more. Journal of Clinical Oncology, 2005
987 citations recorded by the source corpus.
Subfields: Immunology, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/cf72b51ff078e87eefd16e1f6dc9d4fe24593881
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Molecular Biology
In Oncology
Citations in the corpus
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline (2018, background): “Episcleritis is a rare, but clinically important event, occurring in , 1% of treated patients.(124) The management is similar to the”
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma (2010, background): “These include the onset of inflammatory disorders such as colitis, hypophysitis, dermatitis, arthritis, and hepatitis,(28,29) which are reminiscent of autoimmune phenomena and the occurrence of these toxicities may be correlated with tumor regression.(30) In this single arm phase II study, we explor”
- Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis (2007, background): “dose range (all given intravenously every 3wk), the response rate for patients with measurable metastatic melanoma was approximately 13%.(15) Again, as seen with IL-2, many of these responses were of striking durability with some ongoing at their maximum follow-up of over 4 years.”
- gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma (2011, neutral): “Cutaneous or subcutaneous only 8 (9) 8 (9) 0.”
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. (2016, background): “of injections before onset of vitiligo, median (range) 7 (4-31)”
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021, background): “Episcleritis is a rare but clinically important event, occurring in , 1% of treated patients.(218) Ophthalmology referral is recommended for all cases of episcleritis even if asymptomatic and holding immune checkpoint therapy until such evaluation is completed.”
- T Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis (2012, background): “tumor regression in 36% of the patients and was associated with autoimmune toxicity, but patients without autoimmune toxicity were less likely to experience tumor regression (98).”
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2010, positive): “Immune-related AEs (irAEs) were of special interest because of the presumed mechanism of action of anti–PD-1 and prior experience with anti–CTLA-4.(5) No grade 3 irAE occurred in the 28-day period following the first dose of anti–PD-1.”
- Adoptive cell transfer: a clinical path to effective cancer immunotherapy (2008, background): “More recently, antibody-mediated blockade of a cell surface inhibitory molecule, cytotoxic T-lymphocyte-associated 4 ( CTLA4 ), has resulted in objective clinical responses in 10–20% of patients, but again only consistently in those with metastatic melanoma or renal cancer, suggesting that these t”
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis (2015, background): “Another important clinical finding is the lack of evidence that steroid administration affects oncologic response [95, 104]; immunosuppressive agents were used in the event of no early improvement (e.”
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 (2013, background): “It should be noted, however, that these events were more common in patients with the best tumor response to treatment (Attia et al., 2005; Downey et al., 2007).”
- Management of toxicities of immune checkpoint inhibitors. (2016, background): “have been associated with a greater response and survival in some small studies.[52, 79, 80] A retrospective evaluation of 139 patients of ipilimumab given at varying doses also found irAEs to be predictive of response and survival and the highest response rate was seen in those who had grade 3 and ”